Pangestu S, Rencz F. Comprehensive score for financial toxicity and health-related quality of life in patients with cancer and survivors: a systematic review and meta-analysis. Value Health. 2023;26:300–16.
Bhanvadia SK, Psutka SP, Burg ML, de Wit R, Dhillon HM, Gyawali B, Morgans AK, Goldstein DA, Smith AB, Sun M, Penson DF. Financial toxicity among patients with prostate, bladder, and kidney Cancer: a systematic review and call to action. Eur Urol Oncol. 2021;4:396–404.
Ritter J, Allen S, Cohen PD, Fajardo AF, Marx K, Loggetto P, Auste C, Lewis H, de Sá Rodrigues KE, Hussain S, et al. Financial hardship in families of children or adolescents with cancer: a systematic literature review. Lancet Oncol. 2023;24:e364-75.
Sitlinger A, Zafar SY. Health-related quality of life: the impact on morbidity and mortality. Surg Oncol Clin N Am. 2018;27:675–84.
Witte J, Mehlis K, Surmann B, Lingnau R, Damm O, Greiner W, Winkler EC. Methods for measuring financial toxicity after cancer diagnosis and treatment: a systematic review and its implications. Ann Oncol. 2019;30:1061–70.
Carrera PM, Kantarjian HM, Blinder VS. The financial burden and distress of patients with cancer: understanding and stepping-up action on the financial toxicity of cancer treatment. CA Cancer J Clin. 2018;68:153–65.
Gordon LG, Merollini KMD, Lowe A, Chan RJ. A systematic review of Financial Toxicity among Cancer survivors: we can’t pay the co-pay. Patient. 2017;10:295–309.
Jiang H, Lyu J, Mou W, Jiang Q, Du J. Association between financial toxicity and health-related quality of life in cancer survivors: a systematic review. Asia Pac J Clin Oncol. 2023;19:439–57.
Riva S, Arenare L, Di Maio M, Efficace F, Montesarchio V, Frontini L, Giannarelli D, Bryce J, Del Campo L, De Lorenzo F, et al. Cross-sectional study to develop and describe psychometric characteristics of a patient-reported instrument (PROFFIT) for measuring financial toxicity of cancer within a public healthcare system. BMJ Open. 2021;11: e049128.
Dar MA, Chauhan R, Murti K, Trivedi V, Dhingra S. Development and Validation of Subjective Financial Distress Questionnaire (SFDQ): a patient reported Outcome measure for Assessment of Financial Toxicity among Radiation Oncology patients. Front Oncol. 2021;11:819313.
Hueniken K, Douglas CM, Jethwa AR, Mirshams M, Eng L, Hope A, Chepeha DB, Goldstein DP, Ringash J, Hansen A, et al. Measuring financial toxicity incurred after treatment of head and neck cancer: development and validation of the Financial Index of Toxicity questionnaire. Cancer. 2020;126:4042–50.
Zhu Z, Xing W, Zhang X, Hu Y, So WKW. Cancer survivors’ experiences with financial toxicity: a systematic review and meta-synthesis of qualitative studies. Psychooncology. 2020;29:945–59.
Eremenco SL, Cella D, Arnold BJ. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Eval Health Prof. 2005;28:212–32.
Acquadro C, Conway K, Hareendran A, Aaronson N. Literature review of methods to translate health-related quality of life questionnaires for use in multinational clinical trials. Value Health. 2008;11:509–21.
de Souza JA, Yap BJ, Wroblewski K, Blinder V, Araújo FS, Hlubocky FJ, Nicholas LH, O’Connor JM, Brockstein B, Ratain MJ, et al. Measuring financial toxicity as a clinically relevant patient-reported outcome: the validation of the COmprehensive score for financial toxicity (COST). Cancer. 2017;123:476–84.
Durber K, Halkett GK, McMullen M, Nowak AK. Measuring financial toxicity in Australian cancer patients – validation of the COmprehensive score for financial toxicity (FACT COST) measuring financial toxicity in Australian cancer patients. Asia Pac J Clin Oncol. 2021;17:377–87.
Ripamonti CI, Chiesi F, Di Pede P, Guglielmo M, Toffolatti L, Gangeri L, Allocca E. The validation of the Italian version of the COmprehensive score for financial toxicity (COST). Support Care Cancer. 2020;28:4477–85.
Yu HH, Yu ZF, Li H, Zhao H, Sun JM, Liu YY. The COmprehensive score for financial toxicity in China: validation and responsiveness. J Pain Symptom Manage. 2021;61:1297-1304.e1291.
Chan DNS, Choi KC, Ng MSN, Xing W, Law BMH, Ho PS, Au C, Chan M, Tong M, Ling WM, et al. Translation and validation of the traditional Chinese version of the COmprehensive score for financial toxicity-functional Assessment of Chronic Illness Therapy (Version 2). Health Qual Life Outcomes. 2021;19:17.
Mejri N, Rachdi H, Mnif A, Berrazega Y, Benna HE, Labidi S, Boussen H. Translation and validation of the Comprehensive score of Financial Toxicity for Cancer patients into Arabic. J Nurs Meas. 2022;30:673–82.
Honda K, Gyawali B, Ando M, Kumanishi R, Kato K, Sugiyama K, Mitani S, Masuishi T, Narita Y, Bando H, et al. Prospective survey of Financial Toxicity measured by the Comprehensive score for financial toxicity in Japanese patients with Cancer. J Glob Oncol. 2019;5:1–8.
Fradelos EC, Prapa PM, Tsaras K, Papagiannis D, Chatzi M, Papathanasiou IV, Guillen B, Saridi M, Souliotis K. The validation of the COmprehensive score for Financial Toxicity (COST) scale in Greek Language. Adv Exp Med Biol. 2023;1425:191–7.
de Alcantara Nogueira L, Koller FJ, Marcondes L, de Fátima Mantovani M, Marcon SS, Guimarães PRB, Kalinke LP. Validation of the comprehensive score for financial toxicity for Brazilian culture. Ecancermedicalscience. 2020;14:1158.
Pahlevan Sharif S, Moshtagh M, Sim OF, Naghavi N, Sharif Nia H. Psychometric evaluation of the comprehensive score for financial toxicity scale among Iranian cancer patients. J Cancer Policy. 2021;30: 100308.
Kosen S. Coverage and implementation of healthcare delivery for cancer under national health insurance, experience of Indonesia. Lancet Reg Health Southeast Asia. 2022;6:100065.
Fiala MA, Leblanc MR, Coccia KW, Bandaru S, Silberstein AE, Coles T, Vij R. Mixed-methods study on the responsiveness of the comprehensive score for financial toxicity among people with multiple myeloma. JCO Oncol Pract. 2024;20(6):Op2300645.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.
Mokkink LB, Prinsen CAC, Patrick DL, Alonso J, Bouter LM, de Vet HCW, Terwee CB. COSMIN Study Design checklist for Patient-reported outcome measurement instruments (Version July 2019). Amsterdam, the Netherlands: COSMIN; 2019. https://www.cosmin.nl/wp-content/uploads/COSMIN-study-designing-checklist_final.pdf. Accessed 19 Aug 2024.
Hair JF, Babin BJ, Black WC, Anderson RE. Multivariate data analysis. Boston: Cengage; 2019.
FACIT-COST. https://www.facit.org/measures/facit-cost. Accessed 3 Apr 2024.
Terwee CB, Bot SD, de Boer MR, van der Windt DA, Knol DL, Dekker J, Bouter LM, de Vet HC. Quality criteria were proposed for measurement properties of health status questionnaires. J Clin Epidemiol. 2007;60:34–42.
Franklin SB, Gibson DJ, Robertson PA, Pohlmann JT, Fralish JS. Parallel analysis: a method for determining significant principal components. J Veg Sci. 1995;6:99–106.
Comrey AL, Lee HB. A first course in factor analysis. Hove, East Sussex, United Kingdom: Psychology press; 2013.
Li CH. The performance of ML, DWLS, and ULS estimation with robust corrections in structural equation models with ordinal variables. Psychol Methods. 2016;21:369–87.
Whittaker TA. Using the modification index and standardized expected parameter change for model modification. J Experimental Educ. 2012;80:26–44.
Schermelleh-Engel K, Moosbrugger H, Müller H. Evaluating the fit of structural equation models: tests of significance and descriptive goodness-of-fit measures. Methods Psychol Res Online. 2003;8:23–74.
Rosseel Y. Lavaan: an R Package for Structural equation modeling. J Stat Softw. 2012;48:1–36.
Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrika. 1951;16:297–334.
Hayes AF, Coutts JJ. Use omega rather than Cronbach’s alpha for estimating reliability. But…. Commun Methods Measures. 2020;14(1):1–24.
McNeish D. Thanks coefficient alpha, we’ll take it from here. Psychol Methods. 2018;23:412–33.
Tavakol M, Dennick R. Making sense of Cronbach’s alpha. Int J Med Educ. 2011;2:53–5.
Xu RH, Wang LL, Zhou LM, Wong EL, Wang D. Urban-rural differences in financial toxicity and its effect on cancer survivors’ health-related quality of life and emotional status: a latent class analysis. Support Care Cancer. 2022;30:4219–29.
Revicki D, Hays RD, Cella D, Sloan J. Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol. 2008;61:102–9.
Gwet KL. Handbook of inter-rater reliability: the definitive guide to measuring the extent of agreement among raters. Gaithersburg: Advanced Analytics, LLC; 2014.
Koo TK, Li MY. A Guideline of selecting and reporting Intraclass correlation coefficients for Reliability Research. J Chiropr Med. 2016;15:155–63.
Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159–74.
Cohen J. Statistical power analysis for the behavioral sciences. Cambridge: Academic; 2013.
Tran BT, Le DD, Nguyen TG, Nguyen MT, Nguyen MH, Dang CK, Tran DT. Validation of the COmprehensive score for Financial Toxicity (COST) in Vietnamese patients with cancer. PLoS ONE. 2024;19: e0306339.
Carrera PM, Curigliano G, Santini D, Sharp L, Chan RJ, Pisu M, Perrone F, Karjalainen S, Numico G, Cherny N, et al. ESMO expert consensus statements on the screening and management of financial toxicity in patients with cancer. ESMO Open. 2024;9: 102992.
Khan HM, Ramsey S, Shankaran V. Financial toxicity in cancer care: implications for clinical care and potential practice solutions. J Clin Oncol. 2023;41:3051–8.
Liang MI, Harrison R, Aviki EM, Esselen KM, Nitecki R, Meyer L. Financial toxicity: a practical review for gynecologic oncology teams to understand and address patient-level financial burdens. Gynecol Oncol. 2023;170:317–27.
Yuan X, Zhang X, He J, Xing W. Interventions for financial toxicity among cancer survivors: a scoping review. Crit Rev Oncol Hematol. 2023;192:104140.
Aviki EM, Thom B, Braxton K, Chi AJ, Manning-Geist B, Chino F, Brown CL, Abu-Rustum NR, Gany FM. Patient-reported benefit from proposed interventions to reduce financial toxicity during cancer treatment. Support Care Cancer. 2022;30:2713–21.
Fitch MI, Sharp L, Hanly P, Longo CJ. Experiencing financial toxicity associated with cancer in publicly funded healthcare systems: a systematic review of qualitative studies. J Cancer Surviv. 2022;16:314–28.
Smith GL, Banegas MP, Acquati C, Chang S, Chino F, Conti RM, Greenup RA, Kroll JL, Liang MI, Pisu M, et al. Navigating financial toxicity in patients with cancer: a multidisciplinary management approach. CA Cancer J Clin. 2022;72:437–53.
de Souza JA, Yap BJ, Hlubocky FJ, Wroblewski K, Ratain MJ, Cella D, Daugherty CK. The development of a financial toxicity patient-reported outcome in cancer: the COST measure. Cancer. 2014;120:3245–53.
Bridger Staatz C, Kelly Y, Lacey RE, Hardy R. Investigating the factorial structure and measurement invariance of the parent-reported strengths and difficulties questionnaire at 11 years of age from the UK Millennium Cohort Study. Eur Child Adolesc Psychiatry. 2024;33:255–66.
Boothroyd L, Dagnan D, Muncer S. PHQ-9: one factor or two? Psychiatry Res. 2019;271:532–4.
Jiang R, Plunkett SW, Ainsworth AT. Factor structure and validity of the affective style questionnaire. J Health Psychol. 2020;25:1805–15.
Smith W, Vitoratou S, McCrone P, Patel A. Exploring the factor structure of the Health of the Nation outcomes Scale (HoNOS) in a sample of patients with schizophrenia, schizotypal and delusional disorders. Health Qual Life Outcomes. 2017;15:141.
Corrigan KL, Fu S, Chen YS, Kaiser K, Roth M, Peterson SK, Shih YT, Jagsi R, Giordano SH, Volk RJ, et al. Financial toxicity impact on younger versus older adults with cancer in the setting of care delivery. Cancer. 2022;128:2455–62.
Pangestu S, Harjanti EP, Pertiwi IH, Rencz F, Nurdiyanto FA. Financial toxicity experiences of patients with Cancer in Indonesia: an interpretive phenomenological analysis. Value Health Reg Issues. 2023;41:25–31.
Perni S, Azoba C, Gorton E, Park ER, Chabner BA, Moy B, Nipp RD. Financial Toxicity, Symptom Burden, illness perceptions, and communication confidence in Cancer clinical trial participants. JCO Oncol Pract. 2022;18:e1427-1437.
Chan RJ, Gordon LG, Tan CJ, Chan A, Bradford NK, Yates P, Agbejule OA, Miaskowski C. Relationships between financial toxicity and symptom burden in cancer survivors: a systematic review. J Pain Symptom Manage. 2019;57:646-e660641.
Rotter J, Spencer JC, Wheeler SB. Financial toxicity in advanced and metastatic cancer: overburdened and underprepared. J Oncol Pract. 2019;15:e300-307.
Kajimoto Y, Shibutani T, Nagao S, Yamaguchi S, Suzuki S, Mori M, Tsubouchi H, Nakao K, Azuma A, Koyanagi T, et al. Validity of the COmprehensive Score for financial Toxicity (COST) in patients with gynecologic cancer. Int J Gynecol Cancer. 2022;32(9).
Add Comment